BioGaia

Regulatory Filings • Nov 30, 2016

Press Release 30 November 2016

BioGaia makes further investment in MetaboGen

In December 2014 BioGaia reported its decision to invest SEK 12 million in MetaboGen AB, Gothenburg, Sweden. The investment should be made over a two-year period.

The first investment of SEK 4 million took place in December 2014 and the second in December 2015 and as MetaboGen has reached the agreed milestones the last investment of SEK 4 million was made today.

BioGaia thereafter owns 36% of the share capital of MetaboGen.

MetaboGen is a research company, which was founded in 2011 in Gothenburg by Professor Fredrik Bäckhed at the University of Gothenburg and Professor Jens B Nielsen at Chalmers University of Technology together with GU Holding, which commercializes research results and develops companies linked to the University of Gothenburg. MetaboGen researches in metagenomics, the research intensive and fast developing field of gene sequencing of all genes in the microbial communities of for example the human gut, to find previously unknown members and patterns of the microbial diversity related to health and disease. The aim is to develop new treatments and products for different metabolic and other microbial associated diseases by influencing large parts of the microbiota.

Peter Rothschild is Chairman of the Board and Sara Malcus is President in MetaboGen AB.

For further information please see BioGaia´s press release from 1 December 2014 and 2015 on BioGaia´s website: www.biogaia.com/pressreleases

For additional information please contact

Peter Rothschild, Group President, telephone: +46 8 555 293 20 Axel Sjöblad, Managing Director, telephone: +46 8 555 293 00

This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 3 pm CET on 30 November 2016.

Latest press releases from BioGaia

2016-10-31	Disclosure notice in BioGaia
2016-10-25	BioGaia AB Interim Management statement 1 January – 30 September 2016
2016-10-14	BioGaia's probiotics to be launched in Kenya, Nigeria and Ghana

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. biogaia.com